biostudies-literatureWisse LEMNIA NIH HHS1051-1059https://www.ebi.ac.uk/biostudies/studies/S-EPMC11284633biostudies-literatureUnknown81(10)<h4>Importance</h4>The lack of an in vivo measure for α-synuclein (α-syn) pathology until recently has limited thorough characterization of its brain atrophy pattern, especially during early disease stages.<h4>Objective</h4>To assess the association of state-of-the-art cerebrospinal fluid (CSF) seed amplification assays (SAA) α-syn positivity (SAA α-syn+) with magnetic resonance imaging (MRI) structural measures, across the continuum from clinically unimpaired (CU) to cognitively impaired (CI) individuals, in 3 independent cohorts, and separately in CU and CI individuals, the latter reflecting a memory clinic population.<h4>Design, setting, and participants</h4>Cross-sectional data were used from the Swedish BioFINDER-2 study (inclusion, 2017-2023) as the discovery cohort and the Swedish BJAMA neurologyMRI Signature of α-Synuclein Pathology in Asymptomatic Stages and a Memory Clinic Population.PMC11284633R01 AG070592P30 AG066518P30 AG062429Carmichael OBelden CMTaylor JLGrossman HBrewer JRosen HJLane BChertkow HGunter JBonakdarpour BRogalski EMontine TMathis CGeldmacher DCastro KMWu CKRitter AFletcher ELah JJMunic DSalloway SSchwarz CMiller GPeskind ERVaishnavi SKarlawish JHTurner RSPoe JDang MJohnson KARisacher SLAsthana SHosein CBurns JMBecerra MZimmerman CQuinn JSmith CDMecca APWhite JDApostolova LGBrichko RFockler JLandau SFargher KBrosch JRVaron DGoldstein BBorges-Neto SCarter RReynolds BGreen RCRao JSosa EChen SLove MNBurke AChen KPetrie ECJicha GATeodoro LChen SRPomara NHergesheimer LLamb ATideman PFleisher AClark CMTeng EGoldstein MAGarcia ASadowsky CVeitch DNho KSadowski MKhan JIJohnson KKaye JAJohnson NPavlik VPoki-Walker KJohnson SSheikh MOCoker GNosheny RAdegoke OMartinez WKertesz AKass JSHonig LSRafii MLind BJagust WSaykin AJvan Westen DMintz AHeidebrink JLRosen HRosen AScharre DWNam KWAnderson KKittur SVemuri PPetersen RRobson JMez JShen LOliver ABlanchard KSZbizek-Nulph LTosun-Turgut DSenjem MOnyike CYanez BVanderswag HMasliah ESalazar JVarma PKnaack AYushkevich PAShaffer EFleischman DPizzola JSilverman DHSSpann BMStern YBartzokis GSabbagh MBartha RSpotorno NStomrud EStern RWalter SZiolkowski JKnopman DMiller DDMattsson-Carlgren NCairns NJDrost DArfanakis KToga AWMasterman DCabrera YMammana ASantulli RBPerrin RJYesavage JSchneider SPacini NBlank KRelkin NNewhouse PArnold SESperling RAHouseholder EBlack SPearlson GDMudge BBeckett LJack CRLopez OLMesulam MMGraff-Radford NRGreig-Custo MTOgrocki PSossi VLamar MBoles Ponto LLHernando RGrothe MJStefanovic BWilmes KBates VMarson DPotter WZamrini EMuse BHeyn CCKorecka MHarvey DShibley VWard CWisse LEMDas SMatthews BRGrant IDoody RSChowdhury MAlzheimer’s Disease Neuroimaging InitiativeSeltzer MCrissey RPerry DJahanshad NSacrey DTSmith APasternak SSilbert LCWiliams AMarshall GParfitt FDonohue MDaiello LAEl Khouli RSmith SThomopoulos SIAssaly MGoldstein BSShaw LMSink KMKantarci KCrawford KBernard MStobbs-Cucchi GRossi MKowalski NJames OPierce ACarrillo MNwulia EHart DOkonkwo ODeCarli CFigurski MLord JLSloan BTaylor-Reinwald LPetrella JRRachinsky IWoo EHansson ONudelman KCreech MLDuara RCelmins DTicca AParchi PGonzalez HSingleton-Garvin JPawluczyk SLin MMalone IMintun MACapote HNeu SFeldman HKhachaturian ZJones DNeuhaus JConti CNir TMLee TYMartin KSDoraiswamy PMBernick CWeintraub SGreenberg JAisen PClanton TCraft SOtt BRUlysse ABrockington JMacAvoy MGFarrington LFaustin AMintzer JNtekim OEWinkfield DSwerdlow RHTremont GBorowski BHynes MLKoeppe RAAshford MKowall NReiman EMLi GBrand CMCCann KBarnes LRavdin LPerrin ACarlsson CMZimmerman EASchtulz SKMasdeu JBernhardt HPorsteinsson APTingus KSood AMiller BLHsiung GRFranklin ERyan LHajjar IChoe MReid RShah RCLerner AKerwin DFlenniken DChao SVillena TJackson JMason SSRudow SMoore SAtri AGessert DAlbert MFaber KThompson PSamuels PAlbers CSFinger EFox NCStrandberg OBudson AEClark DWolk DAGood SPTinklenberg JIsmail MSThal LMartin KJin CSilverberg NGreig MTFatica PMitsis EColeman JTatsuoka CKielb SMaillard PNadarajah SVaitekunis SKilliany RTarawneh RKataki MQuiceno MOakley MKim EKoleva HChiang GLee ADagerman KFlashman LAMahboubi PHake AMForoud TMKelley BSarrael ARaman RCarson REShi JBrooks WMRainka MForghanian-Arani ASmith KEFarlow MRCarroll MHerring SKremen SLipowski KCleveland JWisniewski TDolen SWolday SKeltz Mvan Dyck CHPalmqvist SMalloy PYang MHo CClark KAGriffith RLu PHReist CWong TZO'Connell AWeiner MWSimpson DMWilliamson JDCorreia SRaslau FDWomack KMathews DAnces BKormos AShim HDrake JWitbracht MBorrie MPotkin SOlichney JRogers JThai GRodriguez RMakino KMCellar JSHsiao JKMarshall GASchneider LSLevey AIObisesan TOShulman MNguyen TTrojanowki JQMorris JCVillaneuva-Meyer JRaj BAJimenez GBaiardi SRountree SfalseMRI Signature of α-Synuclein Pathology in Asymptomatic Stages and a Memory Clinic Population.<h4>Importance</h4>The lack of an in vivo measure for α-synuclein (α-syn) pathology until recently has limited thorough characterization of its brain atrophy pattern, especially during early disease stages.<h4>Objective</h4>To assess the association of state-of-the-art cerebrospinal fluid (CSF) seed amplification assays (SAA) α-syn positivity (SAA α-syn+) with magnetic resonance imaging (MRI) structural measures, across the continuum from clinically unimpaired (CU) to cognitively impaired (CI) individuals, in 3 independent cohorts, and separately in CU and CI individuals, the latter reflecting a memory clinic population.<h4>Design, setting, and participants</h4>Cross-sectional data were used from the Swedish BioFINDER-2 study (inclusion, 2017-2023) as the discovery cohort and the Swedish B2024-01-01T00:00:00Z2024 Oct2026-03-17T13:41:10.42Z2025-08-16T03:05:28.689ZS-EPMC112846333906866810.1001/jamaneurol.2024.2713